Tehran University of Medical Sciences

Science Communicator Platform

Share By
The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to Any Systematic Therapy: A Systematic Review Publisher Pubmed



Mansouri S1 ; Mokhtarihesari P2 ; Naghavialhosseini F1 ; Keivan Majidzadeh A1 ; Farahmand L1
Authors

Source: Current Stem Cell Research and Therapy Published:2019


Abstract

Background: Numerous studies have defined the outstanding role of circulating tumor cells (CTC) in the management of cancer, particularly the ones in association with primary tumor metastases. Objective: The overall aim of the present study was to investigate whether CTCs may serve as a clinical prognostic marker for survival in primary breast cancer. Methods: Articles Published from June 2011 to July 2017 in PubMed, EMBase, and Cochrane library databases were thoroughly screened for selecting the ones meeting the inclusion criteria. Result: Studies applying CellSearch® method demonstrated the risk ratios (RR) of 2.51 (95% CI: 1.78-3.54), 3.98 (95% CI: 2.28-6.95), 5.59 (95% CI: 3.29-9.51), and 3.38 (95% CI: 1.88-6.06) for death rate and relapse rates of 2.48 (95% CI: 1.89-3.26), 3.62 (95% CI: 2.37-5.51), 4.45 (95% CI: 2.94-6.73), and 2.88 (95 % CI: 1.99-4.17) at four CTC positive cut points (≥ 1, ≥ 2, ≥ 3, and ≥ 5 CTCs/7.5 ml). Two studies applying the AdnaTest® also documented increased death (RR: 1.38, 95 % CI: 0.42-4.49) and relapse rates (RR: 2.97, 95 % CI: 1.23-7.18)). Conclusion: Results of this meta-analysis allude CTCs as potent prognostic markers in primary breast cancers prior to any systemic therapy especially when it is studied via CellSearch® administration, considering that the more the CTCs, the greater the death and relapse rates. © 2019 Bentham Science Publishers.
Other Related Docs
11. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
19. Liquid Biopsy in Bladder Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)